Abstract
The cyclic dinucleotides (CDNs) cyclic diguanosine monophosphate (c-diGMP) and cyclic diadenosine monophosphate (c-diAMP) with two canonical 3′→5′ internucleotide linkages are ubiquitous second messenger molecules in bacteria, regulating a multitude of physiological processes. Recently the noncanonical CDN cyclic guanosine monophosphate-adenosine monophosphate (2′3′-cGAMP) featuring a mixed linkage, which consists of a 2′→5′ and a 3′→5′ internucleotide bond, has been identified as a signaling molecule in metazoan species in late 2012. 2′3′-cGAMP formation is biocatalyzed by cGAMP synthase (cGAS) upon sensing of cytosolic double-stranded DNA (dsDNA) and functions as an endogenous inducer of innate immunity by directly binding to and activating the adaptor protein stimulator of interferon genes (STING). Thereby 2′3′-cGAMP can stimulate interferon-β (INF-β) secretion, a major signaling pathway of host defense, which is independent of toll-like receptor (TLR) activation. Medicinal chemistry of 2′3′-cGAMP and development of corresponding analogs are still in their infancy, and only a handful of structurally related compounds are available to the scientific community. The aim of this chapter is to summarize synthetic approaches to prepare canonical and noncanonical endogenous CDNs including 2′3′-cGAMP. Furthermore, we will describe syntheses of 2′3′-cGAMP analogs bearing modifications, which will facilitate further studies of the emerging biological functions of 2′3′-cGAMP and to identify additional receptor proteins. Finally, we will review latest developments concerning 2′3′-cGAMP analogs with improved hydrolytic stability in cell cultures and in tissues, putatively qualifying for new therapeutic options on the basis of 2′3′-cGAMP signaling.
Keywords
1 Introduction
Cyclic diguanosine monophosphate, also known as cyclic bis(3′→5′) diguanylic acid (c-diGMP; c[G(3′,5′)pG(3′,5′)p]), was described in 1987 as an unusual cyclic dinucleotide and allosteric modulator of bacterial cellulose synthase in Acetobacter xylinum (Ross et al. 1987). c-diGMP consists of two guanosine-5′-monophosphates (5′-GMP) forming a 12-membered ring system that contains two phosphate diester units with canonical 3′,5′-bonding (Fig. 1). Meanwhile, c-diGMP is a well-established universal second messenger in the bacterial kingdom with multiple functions, including biofilm formation, motility, and virulence (Jenal and Malone 2006; Römling et al. 2013).
Cyclic diadenosine monophosphate (c-diAMP; c[A(3′,5′)pA(3′,5′)p]; Fig. 1) was identified in 2008 as a signaling nucleotide involved in the regulation of DNA integrity in Bacillus subtilis during sporulation (Witte et al. 2008). In the following years, c-diAMP was found in multiple other bacteria and is now considered as an emerging bacterial second messenger with a steadily increasing number of reports unraveling new cellular functions in prokaryotes (Corrigan and Gründling 2013; Commichau et al. 2015).
Cyclic guanosine monophosphate-adenosine monophosphate (cyclic GMP-AMP; cGAMP) with a combination of adenine and guanine nucleobases was published as the first endogenous CDN representing a second messenger function in metazoa only very recently in 2013 (Sun et al. 2013; Wu et al. 2013). cGAMP is biosynthesized from ATP and GTP by cGAMP synthase (cGAS) upon sensing of cytosolic dsDNA, a typical danger signal in eukaryotic cells. Subsequently, cGAMP activates the adaptor protein stimulator of interferon genes (STING) to induce type 1 interferons and other cytokines as response of the innate immune system. Metazoan cGAMP was originally described as CDN with two canonical 3′,5′-linkages between the 5′-GMP and 5′-AMP units, similar to the almost simultaneously identified bacterial 3′3′-cGAMP (c[G(3′,5′)pA(3′,5′)p]) (Fig. 1) from Vibrio cholerae (Davies et al. 2012). Within some months, several labs investigated the mode of action of metazoan cGAS and characterized the mixed CDN formed with multiple methods, such as crystallography, enzymatic hydrolysis, and chemical synthesis of cGAMP isomers with defined chemical structures (Ablasser et al. 2013; Civril et al. 2013; Diner et al. 2013; Gao et al. 2013; Kranzusch et al. 2013; Zhang et al. 2013). Thereby it was confirmed that in metazoan cGAMP the internucleotide phosphate-binding motifs constituted of a quite uncommon combination of a noncanonical 2′,5′-linkage together with a canonical 3′,5′-linkage (2′3′-cGAMP; c[G(2′,5′)pA(3′,5′)p]; Figs. 1 and 2). The phosphodiester-containing 12-membered ring system in 2′3′-cGAMP is at least theoretically rather flexible and can adopt the syn- or anti-conformation with respect to the two nucleobases adenine and guanine. Also the orientation of each nucleobase toward its dedicated ribose can exist in syn- and anti-conformation as a result of free rotation around the glycosidic bond (N9-C1′). From all hypothetical conformers, in crystals of 2′3′-cGAMP bound to the homodimeric STING protein, the nucleobases adenine and guanine are oriented syn to each other and anti to their corresponding ribose unit (Gao et al. 2013; Zhang et al. 2013). Structure 3 in Fig. 2 depicts these geometric characteristics of STING-bound 2′3′-cGAMP with higher accuracy compared to structures 1 and 2.
There is dramatically increasing evidence that metazoan 2′3′-cGAMP with its immunomodulatory activity can serve as lead for a novel therapeutic paradigm as adjuvant for vaccines or to combat cancer, HIV, and other major diseases related to pathogenic viruses, bacteria, and protozoa. The biological properties of 2′3′-cGAMP are reviewed in detail in Chapter 17 of this book series, whereas the scope of this chapter is to provide a short overview on synthetic routes for the design of canonical and noncanonical CDNs, like 2′3′-cGAMP and related structures. Furthermore, we will describe syntheses which introduce chemical modifications into noncanonical CDNs. The resulting analogs, featuring modulated biological activities, are versatile chemical tools to further investigate the cGAS-2′3′-cGAMP-STING pathway and beyond. Lastly, we will summarize very recent efforts of preclinical testing with 2′3′-cGAMP analogs in cancer pharmacology that may translate into early clinical development in the near future.
2 Syntheses of Canonical CDNs and 2′3′-cGAMP
Over the last 30 years, several syntheses of c-diGMP and c-diAMP have been published, applying phosphate, phosphonate, and phosphite chemistries in solution phase. The majority of these synthetic protocols rely on nucleoside precursors with suitable protection groups to allow for regiospecific reaction steps (Hsu and Dennis 1982; Ross et al. 1990; Hayakawa et al. 2003; Hyodo and Hayakawa 2004; Zhang et al. 2004; Yan and Aguilar 2007; Zhao et al. 2009; Ching et al. 2010; Gaffney et al. 2010). A typical synthetic setup is exemplified in Scheme 1 (Hyodo and Hayakawa 2004).
Several of these protocols were also applied for the synthesis of CDNs bearing two heterogenic nucleobases, like guanine and adenine for the generation of 3′3′-cGAMP, and are carefully reviewed by Shanahan and Strobel (2012). In general, this “nucleoside approach” is convenient for the preparation of small collections of CDNs differing in their nucleobase composition. However, it should be emphasized that most of these protocols include more than 10 synthetic steps accompanied by several chromatographic purifications. In the final CDN the nucleoside combination is defined by the initial selection of nucleoside precursors. This implies that each synthetic process is only suitable to prepare a single cyclic dinucleotide with a unique nucleobase signature. To this end, all these synthetic procedures are not compatible with combinatorial chemistry strategies, a severe drawback limiting the access to a large number of CDN analogs. This obstacle was tackled at least in part by Giese and coworkers (Amiot et al. 2006) with the preparation of a common cyclic ribose-3′,5′-3′,5′-diphosphate building block that was fused with a nucleobase only at the end of the multistep reaction (Scheme 2).
As it stands for now, this improved flexibility of the “backbone approach” was reported only for the preparation of CDNs with identical nucleobases, including c-diGMP and c-diAMP. The generation of heteromeric CDNs should be possible by employing a 1:1 mixture of two distinct nucleobases in the final ribosylation step. However, subsequent separation and purification of heteromeric CDNs and homomeric by-products by HPLC are expected to be challenging and might be prohibitive for a scale-up of this method. In the future, a further elaborated “backbone approach” might qualify for combinatorial strategies to fuse a large number of preactivated nucleobases with a universal cyclic backbone intermediate for the generation of CDN libraries.
While all these reactions are based on solution chemistry, Sintim and coworkers reported a solid-phase approach for the preparation of c-diGMP using a DNA synthesizer and two different guanosine phosphoramidites, including 5′-DMTr-2′-O-TBDMS-guanosine phosphoramidite, carrying a methyl phosphate protection group (Scheme 3) (Kiburu et al. 2008). In this protocol, the cyclization step with 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT) in pyridine (step h in Scheme 3) to prepare the protected CDN was critical with only moderate yields below 50%. Subsequently, in a second-generation approach, the authors cleaved off the protected linear dimer from the solid support prior to quantitative cyclization with MSNT in solution (Kiburu et al. 2008).
Strobel and coworkers further developed syntheses in heterogenic phase (Scheme 4) making use of the most common and commercially available nucleoside phosphoramidites with 5′-DMTr, 2′-O-TBDMS protecting groups, as well as 3′-O-[(2-cyanoethyl)-N,N-diisopropylaminophosphinyl] functionalization (Smith et al. 2010; Shanahan et al. 2011; Smith et al. 2011; Luo et al. 2012; Shanahan et al. 2013).
Quantitative cyclization to generate the protected CDN was accomplished on bead by repeated prolonged treatment with MSNT in pyridine combined with intermittent pyridine washing steps (step j in Scheme 4). As mostly automated syntheses, these solid support methods could be advantageous to solution chemistry to prepare multiple CDNs in a shorter time frame. They could therefore represent a good starting point for effective scale-up and process development of CDN synthesis in the future.
Large-scale and cost-saving syntheses of CDNs are eagerly awaited by the scientific community to have at command sufficient quantities of these second messengers for detailed biological and pharmacological testing. To meet these demands Jones and coworkers developed a solution-phase method, which gives access to c-diGMP as well as related phosphorothioate analogs in a gram scale and is currently considered as state of the art (Scheme 5) (Gaffney et al. 2010).
It uses the common and commercially available precursor A (N2-iBu-5′-O-DMTr-2′-O-TBDMS-3′-O-CEP-guanosine, compare Scheme 5) and is based on phosphoramidite/phosphonate-chemistry protocols established before by this laboratory (Zhang et al. 2004; Zhao et al. 2009). The innovation, however, lies in a carefully chosen synthetic route, applying reaction conditions that allow for the whole process to be performed in a single-flask synthesis without the need for any intermediate purification steps. This improved protocol thus demonstrates a very straightforward and scalable method. Furthermore, after the final deprotection, c-diGMP is simply crystallized from the reaction mixture, avoiding cost-intensive chromatographic purifications throughout the whole reaction sequence. Also the cyclic diguanosine monophosphorodithioate isomers Rp,Rp-c-diGMPSS (c[G(3′,5′)pS-G(3′,5′)pS:Rp,Rp]) and Rp,Sp-c-diGMPSS (c[G(3′,5′)pS-G(3′,5′)pS:Rp,Sp]) were prepared with this improved method employing sulfurization instead of oxidation reagents (Scheme 5, Fig. 3).
Here, only a single purification step for the separation of Rp,Rp- and Rp,Sp-isomers is necessary. In these dithiophosphates of c-diGMP, the terms “Rp” and “Sp” refer to the different isomers of the sulfur-modified and thus chiral phosphorus atoms of the 12-membered ring system of cyclic dinucleotides according to the Cahn-Ingold-Prelog priority rules (CIP). The isomer Sp,Sp-c-diGMPSS (c[G(3′,5′)pS-G(3′,5′)pS:Sp,Sp]; (Zhao et al. 2009) is chemically not accessible by this synthetic protocol as a result of the stereoselective introduction of sulfur into the phosphonate intermediate with 3-H-1,2-benzodithiol-3-one (compare Fig. 3, step h; Scheme 5).
Shortly after the first reports of metazoan cGAMP (Sun et al. 2013; Wu et al. 2013), Jones and coworkers adapted their single-flask c-diGMP protocol to be applicable for the synthesis of mixed cyclic dinucleotides containing adenine and guanine (Gao et al. 2013). With the modified procedure in hands, they succeeded in preparing several cGAMP isomers with canonical and noncanonical linkages. In particular, to facilitate the 2′-5′ linkages, they interchanged the 2′- and 3′-functionalities of the second precursor (Scheme 6).
The synthetically prepared and structurally defined 2′3′-cGAMP, applied as HPLC reference, helped to confirm the chemical identity of native metazoan cGAMP. Meanwhile, this single-flask protocol was successfully established in other laboratories, partially modified and used to prepare 2′3′-cGAMP and analogs in larger scale (D. Kashin et al., unpublished results; Dubensky et al. 2014; Zhang et al. 2013)
3 Syntheses of 2′3′-cGAMP Analogs
3.1 Analogs with Modifications in the Nucleobase and Ribose Moieties
2′3′-cGAMP analogs with meaningful chemical modifications are thought to be useful tools for a more detailed insight into the recently unraveled cGAS-2′3′-cGAMP-STING pathway. They can also support the identification of additional receptor proteins in this emerging scientific field of noncanonical cyclic dinucleotides in eukaryotes. We set out to generate 2′3′-cGAMP analogs with functional spacers in different positions of the molecule to be employed for interaction studies with STING and for a chemical proteomics approach to search for additional binding proteins. For this task, we selected position 8 of the guanine moiety and the 2′-OH/3′-OH groups of the ribose parts of 2′3′-cGAMP for a first generation of chemical interventions. Regioselective introduction of bromine into position 8 of guanine was accomplished by reacting 2′3′-cGAMP with bromine in aqueous solution at ambient temperature (Scheme 7). Under these conditions only guanine, but not the equivalent position in adenine, is susceptible to bromination, leading to 8-Br-2′3′-cGAMP (c[8-Br-G(2′,5′)pA(3′,5′)p]), the first 2′3′-cGAMP analog with a single modification in the nucleobase.
Nucleophilic substitutions of 8-bromoguanine-containing nucleosides and nucleotides with standard aminoalkylamino reagents are only possible in sealed containers under harsh conditions at temperatures of up to 160°C (Ikehara and Muneyama 1966; Brown et al. 1993). The alternative thiol groups in ω-aminoalkylthiol reagents are better nucleophiles and commonly used to connect terminal aminoalkyl spacers with thioether linkage to position 8 of guanine. Therefore, 8-Br-2′3′-cGAMP was further reacted with aminoethylthiol (AET) under alkaline conditions at moderate temperatures (50-70°C) to yield cyclic 8-AET-2′3′-cGAMP (c[8-AET-G(2′,5′)pA(3′,5′)p]) (Scheme 7). Introduction of hexyl spacers with a terminal amino group into 2′- and 3′-positions of 2′3′-cGAMP was accomplished according to Hammerschmidt et al. by initial activation of the lipophilic bis-diisopropylethylammonium salt of 2′3′-cGAMP with 1,1′-carbonyldiimidazole under in anhydrous DMF, followed by addition of excess 1,6-diaminohexane (Hammerschmidt et al. 2012). The raw mixture of 2′-AHC-2′3′-cGAMP (c[G(2′,5′)p-2′-AHC-A(3′,5′)p]) and 3′-AHC-2′3′-cGAMP (c[3′-AHC-G(2′,5′)pA(3′,5′)p]) (Scheme 8) was purified by HPLC to isolate the spacer-modified 2′- and 3′-isomers of 2′3′-cGAMP. All analogs with functionalized spacers can serve as precursors for further chemical modifications, including immobilization on agarose beads, coupling to chips for surface plasmon resonance experiments, and labeling with reporter groups like biotin or fluorescent dyes.
Furthermore, after coupling to haptens these functionalized 2′3′-cGAMP analogs can be suitable tools for antibody generation and subsequent development of immunoassays for 2′3′-cGAMP. Such immunoassays could be employed to simplify the detection and quantification of 2′3′-cGAMP in biological matrices. Currently, the state of the art is still highly sophisticated HPLC-MS/MS analytics, which has sufficient detection sensitivities, but depends on high-end HPLC-MS hardware, precluding its broad application as routine method (compare Chapter XY of this book series).
Immobilization on agarose beads was initiated by reacting the spacer-containing 2′3′-cGAMP analogs with N-hydroxysuccinimide ester (NHS)-activated agarose in anhydrous DMSO in the presence of a non-nucleophilic base like diisopropylethylamine as described in Bertinetti et al. (Scheme 9) (Bertinetti et al. 2009).
Potential applications of the resulting tools 8-AET-2′3′-cGAMP-agarose, 2′-AHC-2′3′-cGAMP-agarose, and 3′-AHC-2′3′-cGAMP-agarose are not only affinity purifications of STING, but also the screening for additional interaction partners of STING, which should co-elute during chromatography or co-precipitate in pulldown experiments. Furthermore, these agaroses could be employed in the quest for new binding proteins of 2′3′-cGAMP in metazoa.
In this regard, it is of interest that CDNs, including 2′3′-cGAMP, have been reported to bind to a newly identified C-linker binding pocket (CLP) in the cytosolic C-linker region of the hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4), the main isoform of the cardiac pacemaker (Lolicato et al. 2014). HCN4 is activated by hyperpolarization of membrane voltage in myocytes, and its open probability is controlled and prolonged by cAMP binding to the cyclic nucleotide-binding domain, which is separate from the CLP site. Upon binding to CLP, 2′3′-cGAMP and bacterial CDNs were shown to antagonize cAMP regulation of the channel leading to an efficient reduction of heart rate by 30%. This first report about a putative signaling role of 2′3′-cGAMP apart from the innate immunity system highlights that physiological roles of 2′3′-cGAMP in mammals are far from being fully evaluated, including the existence of additional protein-binding partners that may be identified by the chemical proteomics approach with 2′3′-cGAMP-agaroses as affinity baits.
Biotinylated analogs of the canonical bacterial second messengers c-diGMP and c-diAMP were synthesized by Beaucage and coworkers (Grajkowski et al. 2010) and in our laboratory. Biotinylated c-diGMP analogs were shown to interact with certain previously established c-diGMP binders (Luo et al. 2012) and, after coupling to streptavidin beads, were suitable to isolate putative c-diGMP interacting proteins from murine macrophages after challenge with Legionella pneumophila (Abdul-Sater et al. 2012). 2′-[Biotin]-AHC-c-diAMP was used to develop a c-diAMP ELISA (Bai et al. 2013) and after immobilization on streptavidin-coated magnetic beads, employed for the identification of new receptor proteins from Staphylococcus aureus and Bacillus subtilis in pulldown assays (Corrigan et al. 2013; Gundlach et al. 2015). To enable comparable studies in the field of metazoan 2′3′-cGAMP, the ω-aminospacer-containing analogs 8-AET-2′3′-cGAMP, 2′-AHC-2′3′-cGAMP and 3′-AHC-2′3′-cGAMP were reacted with biotinamidocaproate-NHS ester ([Biotin]-NHS) in borate buffer pH 9/2-propanol. Raw mixtures were subsequently purified with ion exchange and reversed phase chromatography to remove unreacted starting material and hydrolyzed biotinamidocaproic acid contaminations, leading to 8-[Biotin]-AET-2′3′-cGAMP (c[8-[Biotin]-AET-G(2′,5′)pA(3′,5′)p]), 2′-[Biotin]-AHC-2′3′-cGAMP (c[G(2′,5′)p-2′-[Biotin]-AHC-A(3′,5′)p]), and 3′-[Biotin]-AHC-2′3′-cGAMP (c[3′-[Biotin]-AHC-G(2′,5′)pA(3′,5′)p]), respectively (Fig. 4).
As was shown for the biotinylated derivatives of bacterial second messengers in recent years, these new biotinylated noncanonical congeners are expected to serve as valuable tools for further characterization of 2′3′-cGAMP signaling in eukaryotes.
The fluorescein-labeled analog 2′-Fluo-AHC-c-diGMP is commercially available and was employed to detect c-diGMP-binding proteins in c-diGMP-agarose eluates, thereby avoiding radioactive assays (Düvel et al. 2012). This compound was also used to develop a fluorescence polarization-based assay to measure binding affinities of flavonoid-based agonists of mouse STING that compete for the CDN binding site (Kim et al. 2013). Very recently, 2′-Fluo-AHC-c-diGMP was applied to determine binding affinities of c-diGMP to receptor proteins with microscale thermophoresis coupled to fluorescence detection (Sundriyal et al. 2014). 2′-MANT-c-diGMP and 2′,2″-Di-MANT-c-diGMP containing the fluorescent and environmentally sensitive N-methylanthranilic (MANT) dye were used for the characterization of c-diGMP-binding proteins (Sharma et al. 2012) and for staining of putative c-diGMP-binding partners in cytosolic vesicles of macrophages after Legionella pneumophila challenge (Abdul-Sater et al. 2012). Given the variety of potential applications for fluorescently labeled 2′3′-cGAMP, we prepared a first series of fluorescein-containing analogs. For this purpose, we reacted 8-AET-2′3′-cGAMP, 2′-AHC-2′3′-cGAMP, and 3′-AHC-2′3′-cGAMP with 5-carboxyfluorescein-NHS ester in borate buffer pH 9/DMSO. The reaction products 8-Fluo-AET-2′3′-cGAMP (c[8-Fluo-AET-G(2′,5′)pA(3′,5′)p]), 2′-Fluo-AHC-2′3′-cGAMP (c[G(2′,5′)p-2′-Fluo-AHC-A(3′,5′)p]), and 3′-Fluo-AHC-2′3′-cGAMP (c[3′-Fluo-AHC-G(2′,5′)pA(3′,5′)p]) (Fig. 5) were purified by repeated reversed phase chromatography to remove fluorescent impurities. The synthesis of MANT- and di-MANT-substituted 2′3′-cGAMP and other related fluorescent analogs are ongoing projects in our laboratory.
4 Syntheses of 2′3′-cGAMP Analogs
4.1 Analogs with Modifications in the Phosphate and Ribose Moieties
In 2014, Mitchison and coworkers identified ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) as dominant endogenous hydrolase of 2′3′-cGAMP in an activity-guided screening and protein purification sequence from calf liver (Li et al. 2014). ENPP1 belongs to the ENPP family consisting of three members (ENPP1-3) and is described as a membrane-associated glycoprotein with an extracellular active site of high ATPase activity. Furthermore, ENPP1 can be released into serum and exists as a functional soluble enzyme (Belli et al. 1993). The protein has only weak substrate specificity and cleaves a variety of pyrophosphate bonds in nucleotides, including ATP, ADP, NAD+, ADP-ribose, FAD, CoA, and diadenosine polyphosphates, leading to 5′-AMP. Also UDP-glucose and other pyrimidine nucleotides may serve as substrates (Bollen et al. 2000; Cimpean et al. 2004). In incubations with recombinant ENPP1, 2′3′-cGAMP is hydrolyzed efficiently with similar kinetics as the natural substrate ATP. Given this apparent instability of the natural metazoan second messenger, the bacterial 3′3′-cGAMP and a set of 2′3′-cGAMP analogs with modifications in the ribose or the phosphate moiety were synthesized and tested for improved hydrolytic resistance against ENPP1 (Li et al. 2014). 3′3′-cGAMP was prepared chemoenzymatically from ATP and GTP by dinucleotide cyclase (DncV), an endogenous cyclase from Vibrio cholerae (Scheme 10) (Davies et al. 2012). All noncanonical CDNs were enzymatically synthesized with cGAS, which was activated by DNA from herring testes (HT DNA), and appropriately modified ATP and GTP analogs. Incubation of 3′-deoxy-GTP with ATP resulted in 3′-deoxy-2′3′-cGAMP (c[3′-dG(2′,5′)pA(3′,5′)p]) (Scheme 10), which showed a half-life of approx. 1 h in ENPP1 hydrolase assays, comparable to 2′3′-cGAMP itself. By contrast, the mono- and dithiophosphate analogs 2′3′-cGSAMP (c[G(2′,5′)pS-A(3′,5′)p]), 2′3′-cGASMP (c[G(2′,5′)p-A(3′,5′)pS]) with sulfur either in the 2′,5′- or 3′,5′-linkage and 2′3′-cGAMPSS (2′3′-cGSASMP) (Scheme 10) demonstrated significantly improved hydrolytic stability against ENPP1. The half-life of all thiophosphate-containing CDNs was in the range of 24 h or even longer. This is in accordance with former reports about increased biological stabilities of sulfur-containing nucleoside phosphorothioates compared to unmodified phosphodiesters in cyclic nucleotides, triphosphates, or oligonucleotides (Eckstein and Gish 1989; Schwede et al. 2000; Eckstein 2014). 2′3′-cGSAMP, 2′3′-cGASMP, and 2′3′-cGAMPSS were prepared by incubation of cGAS with ATP, GTP, ATP-α-S, and GTP-α-S in different combinations. In this particular chemoenzymatic protocol, diastereomeric mixtures of Rp- and Sp-ATP-α-S and GTP-α-S were used for the biocatalyzed syntheses, and the reaction products were not fully characterized with respect to their diastereomeric composition of distinct isomers. A careful evaluation of both potentially stereoselective events, the enzymatic substrate recognition and the cyclization step by cGAS, is thought to be possible with commercially available pure Rp- and Sp-isomers of ATP-α-S and GTP-α-S. 3′-Deoxy-2′3′-cGAMP and 2′3′-cGAMPSS were shown to bind to human STING with high affinities in the low nanomolar concentration range, comparable to endogenous 2′3′-cGAMP. Subsequently, these analogs were further tested against 2′3′-cGAMP for their ability to activate human STING in cell culture in long-term incubations of 24 h. Of all analogs tested, the nonhydrolyzable 2′3′-cGAMPSS exhibited highest levels of INF-β induction in human THP-1 cells expressing STING. The effective concentration (EC50) was ~5 μM for 2′3′-cGAMPSS, approximately tenfold lower compared to 2′3′-cGAMP. From additional experiments with lung fibroblast cells from Enpp1 -/- mice with similar EC50-values for both CDNs, the authors concluded that the improved EC50-value of 2′3′-cGAMPSS was due to increased biostability compared to 2′3′-cGAMP (Li et al. 2014). In summary, 2′3′-cGAMPSS was recognized as superior lead for further therapeutic development. Interestingly, also the bacterial 3′3′-cGAMP was found to be stable against hydrolysis by ENPP1. Albeit 3′3′-cGAMP had a 50- to 100-fold reduced binding affinity toward human STING in vitro, its improved hydrolytic stability resulted in similar activatory potentials of 3′3′-cGAMP and 2′3′-cGAMP, with EC50-values of ~50 μM for INF-β induction in human THP-1 cells. These initial results opened up another track for future medicinal chemistry interventions to develop CDN-based STING activators with prolonged stability in biological systems.
Applying the general chemical sequence reported by Gaffney et al. (2010), a series of phosphate-based and phosphorothioate-modified CDNs with canonical and noncanonical linkages have been prepared and tested for their biological activity (Dubensky Jr et al. 2014; Corrales et al. 2015; Fu et al. 2015). Besides phosphate-containing CDNs, also the pure isomers Rp,Rp-2′3′-cGAMPSS, Rp,Sp-2′3′-cGAMPSS, Rp,Rp-2′3′-c-diAMPSS, Rp,Sp-2′3′-c-diAMPSS, Rp,Rp-2′3′-c-diGMPSS, and Rp,Sp-2′3′-c-diGMPSS (Fig. 6) were synthesized from commercially available nucleoside phosphoramidites and purified by HPLC.
The resulting analogs were tested for binding to and activation of STING wild type (WT) and four different haplotypes of human STING protein genotypes (REF, HAQ, AQ, and Q alleles), varying in amino acid positions 71, 230, 232, and 293. These single nucleotide polymorphisms were reported to affect innate immune signaling (Jin et al. 2011; Yi et al. 2013). As reported earlier, highest binding affinity for wild type human STINGWT was achieved by analogs with noncanonical linkage, namely 2′3′-cGAMP, Rp,Rp-2′3′-cGAMPSS, and Rp,Rp-2′3′-c-diAMPSS (Corrales et al. 2015). For activity screening each of the five STING variants was stably expressed in HEK293T cells, which are negative in endogenous STING. Induction of INF-β was monitored by co-transfection of a IFN-β-luciferase construct. Bacterial CDNs c-diGMP, c-diAMP, and 3′3′-cGAMP were able to induce IFN-β in genotypes hSTINGWT, hSTINGHAQ, and hSTINGAQ, but not in hSTINGREF and hSTINGQ. By contrast, the noncanonical endogenous 2′3′-cGAMP, Rp,Rp-2′3′-cGAMPSS, Rp,Rp-2′3′-c-diAMPSS, and Rp,Rp-2′3′-c-diGMPSS were able to induce an IFN response in all STING variants tested (Corrales et al. 2015). In an alternative protocol, the murine bone marrow-derived dendritic cell line DC2.4 was used for INF-β induction and to compare noncanonical 2′3′-c-diAMP with its corresponding diphosphorothioate congeners Rp,Rp-2′3′-c-diAMPSS and Rp,Sp-2′3′-c-diAMPSS (Fu et al. 2015). Highest levels of INF-β were detected after treatment with Rp,Rp-2′3′-c-diAMPSS. The isomeric Rp,Sp-2′3′-c-diAMPSS generated only a moderately increased INF-β level, similar to 2′3′-c-diAMP. STING signaling was further evaluated with canonical and noncanonical CDNs in peripheral blood mononuclear cells (PBMC) from human donors with different STING genotypes. In these assays the diphosphorothioated analogs Rp,Rp-2′3′-cGAMPSS, Rp,Rp-2′3′-c-diAMPSS, and Rp,Rp-2′3′-c-diGMPSS induced significantly higher levels of INF-β than canonical or noncanonical CDNs without sulfur modification (Corrales et al. 2015; Fu et al. 2015). As a consequence of their superior and pan-genetic activity, Rp,Rp-isomers of diphosphorothioated noncanonical CDNs were selected for further preclinical development and tested in mice bearing different solid tumor models. Upon intratumoral injection Rp,Rp-2′3′-c-diAMPSS not only significantly reduced tumor growth with a higher therapeutic index compared to Rp,Rp-2′3′-c-diGMPSS but also induced a profound systemic immune response eligible to combat metastases distant to the injection site. Importantly, the formulation of Rp,Rp-2′3′-c-diAMPSS as adjuvant together with a granulocyte-macrophage colony-stimulating factor (GM-CSF) secreting tumor cell vaccine (STINGVAX(RR-S2-CDA)) produced a strongly enhanced antitumor response in several solid tumor models in mice. This pharmacological effect was significantly higher when compared with the vaccine alone, formulations with canonical 3′3′-c-diAMP (STINGVAX(CDA)), or formulations with other control adjuvants (Fu et al. 2015). In conclusion, Rp,Rp-2′3′-c-diAMPSS was selected as the most promising and first noncanonical CDN for further clinical development as potential anticancer medicine (Corrales et al. 2015).
5 Conclusion and Future Perspectives
The noncanonical CDN 2′3′-cGAMP was identified as an endogenous small second messenger molecule in metazoa in late 2012. It soon became clear that 2′3′-cGAMP has a central function in innate immunity by activating STING leading to subsequent induction of IFN-β, a major pathway to combat cancer or other severe diseases caused by infections with pathogenic bacteria, protozoa, and viruses. Fortunately, a fast adaption of synthetic protocols originally established for canonical CDNs (Gaffney et al. 2010) to 2′3′-cGAMP was possible with commercially available nucleoside phosphoramidite precursors. Thereby sufficient amounts of 2′3′-cGAMP were made available for intensive biological testing of the cGAS-2′3′-cGAMP-STING pathway in several laboratories.
2′3′-cGAMP was modified in different positions (C-8 of guanine, 2′-OH and 3′-OH of riboses) with functional spacers eligible for coupling to agarose beads or for the introduction of reporter groups, like biotin, digoxigenin, and fluorescent dyes. This new toolkit is thought to facilitate the identification of so far unknown STING- or ENPP1-interacting proteins and the quest for new primary receptors of 2′3′-cGAMP signaling. New 2′3′-cGAMP analogs with reporter groups will enable an in-depth biochemical characterization of protein-CDN interactions, as was already proven successful with corresponding bacterial CDNs. 8-Fluo-AET-2′3′-cGAMP, 2′-Fluo-AHC-2′3′-cGAMP, and 3′-Fluo-AHC-2′3′-cGAMP are molecular probes that may be used to establish fluorescence-based binding assays for 2′3′-cGAMP and analogs at receptor proteins. Moreover, analogs like 8-AET-2′3′-cGAMP, 2′-AHC-2′3′-cGAMP, and 3′-AHC-2′3′-cGAMP are convenient starting points for the development of antibodies against 2′3′-cGAMP and for immunoassays to simplify the quantification of 2′3′-cGAMP in biological systems like cells and tissues.
Diphosphorothioate-modified noncanonical CDNs were shown to have significantly improved stability against hydrolysis by ENPP1 in vivo combined with preserved binding affinities and activatory potential for several genotypes of human STING protein. From this class of sulfur-containing CDNs, Rp,Rp-2′3′-c-diAMPSS exhibited pharmacological characteristics justifying further preclinical development work and putative transition into the clinical phase within only 3 years after the identification of 2′3′-cGAMP. In this context, it will be of high importance to create sophisticated analogs of Rp,Rp-2′3′-c-diAMPSS or related CDNs with modifications in multiple positions of their unique chemical architecture to fully evaluate the pharmacological potency of these new therapeutic lead structures.
Despite enormous achievements that have been accomplished thanks to intensive research during the last years, it should be emphasized that larger collections or libraries of differently modified analogs of 2′3′-cGAMP are only hardly accessible with currently established chemical methods. All “nucleoside approaches” require a minimum of eight chemical steps, rely on available preformed nucleoside phosphoroamidites with several protection groups, and yield only a single or two CDN analogs. It should be noted that most nucleobase modifications or ribose modifications have to be introduced on the nucleoside level often via multiple chemical steps prior to formation of the nucleoside phosphoroamidite. In addition, such modifications have to withstand and should not interfere with reaction conditions of subsequent CDN formation. All these framework conditions are bottlenecks and prohibit the synthesis of libraries of CDN analogs in the midterm. A modification of the antipodal “backbone approach” (Amiot et al. 2006) with alternative common cyclic ribose-2′,5′-3′,5′-diphosphate or cyclic ribose-2′,5′-3′,5′-diphosphorothioate building blocks could be a practicable starting point for the development of parallel syntheses or combinatorial chemistry procedures to generate a larger number of nucleobase-modified noncanonical CDNs. As long as this general drawback has not been overcome by innovative chemical approaches, the design and preparation of new 2′3′-cGAMP analogs will not pick up pace but will require multiple step protocols to obtain single compounds.
References
Abdul-Sater AA, Grajkowski A, Erdjument-Bromage H, Plumlee C, Levi A, Schreiber MT, Lee C, Shuman H, Beaucage SL, Schindler C (2012) The overlapping host responses to bacterial cyclic dinucleotides. Microbes Infect 14(2):188–197. doi:10.1016/j.micinf.2011.09.002
Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V (2013) cGAS produces a 2′-5'-linked cyclic dinucleotide second messenger that activates STING. Nature 498(7454):380–384. doi:10.1038/nature12306
Amiot N, Giese B, Heintz K (2006) New approach for the synthesis of c-di-GMP and its analogues. Synthesis 2006(24):4230–4236. doi:10.1055/s-2006-950361
Bai Y, Yang J, Eisele LE, Underwood AJ, Koestler BJ, Waters CM, Metzger DW, Bai G (2013) Two DHH subfamily 1 proteins in Streptococcus pneumoniae possess cyclic di-AMP phosphodiesterase activity and affect bacterial growth and virulence. J Bacteriol 195(22):5123–5132. doi:10.1128/JB.00769-13
Belli SI, van Driel IR, Goding JW (1993) Identification and characterization of a soluble form of the plasma cell membrane glycoprotein PC-1 (5'-nucleotide phosphodiesterase). Eur J Biochem 217(1):421–428
Bertinetti D, Schweinsberg S, Hanke SE, Schwede F, Bertinetti O, Drewianka S, Genieser HG, Herberg FW (2009) Chemical tools selectively target components of the PKA system. BMC Chem Biol 9:3. doi:10.1186/1472-6769-9-3
Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C (2000) Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 35(6):393–432. doi:10.1080/10409230091169249
Brown RL, Bert RJ, Evans FE, Karpen JW (1993) Activation of retinal rod cGMP-gated channels: what makes for an effective 8-substituted derivative of cGMP? Biochemistry 32(38):10089–10095
Ching SM, Tan WJ, Chua KL, Lam Y (2010) Synthesis of cyclic di-nucleotidic acids as potential inhibitors targeting diguanylate cyclase. Bioorg Med Chem 18(18):6657–6665. doi:10.1016/j.bmc.2010.07.068
Cimpean A, Stefan C, Gijsbers R, Stalmans W, Bollen M (2004) Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2. Biochem J 381(Pt 1):71–77. doi:10.1042/BJ20040465
Civril F, Deimling T, de Oliveira Mann CC, Ablasser A, Moldt M, Witte G, Hornung V, Hopfner KP (2013) Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498(7454):332–337. doi:10.1038/nature12305
Commichau FM, Dickmanns A, Gundlach J, Ficner R, Stülke J (2015) A jack of all trades: the multiple roles of the unique essential second messenger cyclic di-AMP. Mol Microbiol. doi:10.1111/mmi.13026
Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF (2015) Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 11(7):1018–1030. doi:10.1016/j.celrep.2015.04.031
Corrigan RM, Gründling A (2013) Cyclic di-AMP: another second messenger enters the fray. Nat Rev Microbiol 11(8):513–524. doi:10.1038/nrmicro3069
Corrigan RM, Campeotto I, Jeganathan T, Roelofs KG, Lee VT, Gründling A (2013) Systematic identification of conserved bacterial c-di-AMP receptor proteins. Proc Natl Acad Sci U S A 110(22):9084–9089. doi:10.1073/pnas.1300595110
Davies BW, Bogard RW, Young TS, Mekalanos JJ (2012) Coordinated regulation of accessory genetic elements produces cyclic di-nucleotides for V. Cholerae virulence. Cell 149(2):358–370. doi:10.1016/j.cell.2012.01.053
Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, Hayakawa Y, Hammond MC, Vance RE (2013) The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep 3(5):1355–1361. doi:10.1016/j.celrep.2013.05.009
Dubensky TW Jr, Kanne DB, Leong MLL, Glickman LH, Vance RE, Lemmens EE (2014) Composotions and methods for activating “stimulator of interferon gene”-dependent signalling. WO/2014/189805
Düvel J, Bertinetti D, Möller S, Schwede F, Morr M, Wissing J, Radamm L, Zimmermann B, Genieser HG, Jänsch L, Herberg FW, Häussler S (2012) A chemical proteomics approach to identify c-di-GMP binding proteins in Pseudomonas aeruginosa. J Microbiol Methods 88(2):229–236. doi:10.1016/j.mimet.2011.11.015
Eckstein F (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24(6):374–387. doi:10.1089/nat.2014.0506
Eckstein F, Gish G (1989) Phosphorothioates in molecular biology. Trends Biochem Sci 14(3):97–100
Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE, Zeng Q, Soares KC, Zheng L, Portnoy DA, Woodward JJ, Pardoll DM, Dubensky TW Jr, Kim Y (2015) STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med 7(283):283ra252. doi:10.1126/scitranslmed.aaa4306
Gaffney BL, Veliath E, Zhao J, Jones RA (2010) One-flask syntheses of c-di-GMP and the [Rp, Rp] and [Rp, Sp] thiophosphate analogues. Org Lett 12(14):3269–3271. doi:10.1021/ol101236b
Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, Zillinger T, Serganov AA, Liu Y, Jones RA, Hartmann G, Tuschl T, Patel DJ (2013) Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153(5):1094–1107. doi:10.1016/j.cell.2013.04.046
Grajkowski A, Cieslak J, Gapeev A, Schindler C, Beaucage SL (2010) Convenient synthesis of a propargylated cyclic (3′-5′) diguanylic acid and its “click” conjugation to a biotinylated azide. Bioconjug Chem 21(11):2147–2152. doi:10.1021/bc1003857
Gundlach J, Dickmanns A, Schröder-Tittmann K, Neumann P, Kaesler J, Kampf J, Herzberg C, Hammer E, Schwede F, Kaever V, Tittmann K, Stülke J, Ficner R (2015) Identification, characterization, and structure analysis of the cyclic di-AMP-binding PII-like signal transduction protein DarA. J Biol Chem 290(5):3069–3080. doi:10.1074/jbc.M114.619619
Hammerschmidt A, Chatterji B, Zeiser J, Schröder A, Genieser HG, Pich A, Kaever V, Schwede F, Wolter S, Seifert R (2012) Binding of regulatory subunits of cyclic AMP-dependent protein kinase to cyclic CMP agarose. PLoS One 7(7), e39848. doi:10.1371/journal.pone.0039848
Hayakawa Y, Nagata R, Hirata A, Hyodo M, Kawai R (2003) A facile synthesis of cyclic bis(3 ′- > 5 ′)diguanylic acid. Tetrahedron 59(34):6465–6471. doi:10.1016/S0040-4020(03)01045-7
Hsu CY, Dennis D (1982) RNA polymerase: linear competitive inhibition by bis-(3′ to 5′)-cyclic dinucleotides. Nucleic Acids Res 10(18):5637–5647
Hyodo M, Hayakawa Y (2004) An improved method for synthesizing cyclic bis(3′-5′)diguanylic acid (c-di-GMP). Bull Chem Soc Jpn 77(11):2089–2093. doi:10.1246/bcsj.77.2089
Ikehara M, Muneyama K (1966) Studies of nucleosides and nucleotides. 30. Syntheses of 8-substituted guanosine derivatives. Chem Pharm Bull (Tokyo) 14(1):46–49
Jenal U, Malone J (2006) Mechanisms of cyclic-di-GMP signaling in bacteria. Annu Rev Genet 40:385–407. doi:10.1146/annurev.genet.40.110405.090423
Jin L, Xu LG, Yang IV, Davidson EJ, Schwartz DA, Wurfel MM, Cambier JC (2011) Identification and characterization of a loss-of-function human MPYS variant. Genes Immun 12(4):263–269. doi:10.1038/gene.2010.75
Kiburu I, Shurer A, Yan L, Sintim HO (2008) A simple solid-phase synthesis of the ubiquitous bacterial signaling molecule, c-di-GMP and analogues. Mol Biosyst 4(6):518–520. doi:10.1039/b719423d
Kim S, Li L, Maliga Z, Yin Q, Wu H, Mitchison TJ (2013) Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol 8(7):1396–1401. doi:10.1021/cb400264n
Kranzusch PJ, Lee AS, Berger JM, Doudna JA (2013) Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep 3(5):1362–1368. doi:10.1016/j.celrep.2013.05.008
Li L, Yin Q, Kuss P, Maliga Z, Millan JL, Wu H, Mitchison TJ (2014) Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol 10(12):1043–1048. doi:10.1038/nchembio.1661
Lolicato M, Bucchi A, Arrigoni C, Zucca S, Nardini M, Schroeder I, Simmons K, Aquila M, DiFrancesco D, Bolognesi M, Schwede F, Kashin D, Fishwick CW, Johnson AP, Thiel G, Moroni A (2014) Cyclic dinucleotides bind the C-linker of HCN4 to control channel cAMP responsiveness. Nat Chem Biol 10(6):457–462. doi:10.1038/nchembio.1521
Luo Y, Zhou J, Watt SK, Lee VT, Dayie TK, Sintim HO (2012) Differential binding of 2′-biotinylated analogs of c-di-GMP with c-di-GMP riboswitches and binding proteins. Mol Biosyst 8(3):772–778. doi:10.1039/c2mb05338a
Römling U, Galperin MY, Gomelsky M (2013) Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol Mol Biol Rev 77(1):1–52. doi:10.1128/MMBR.00043-12
Ross P, Weinhouse H, Aloni Y, Michaeli D, Weinberger-Ohana P, Mayer R, Braun S, de Vroom E, van der Marel GA, van Boom JH, Benziman M (1987) Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature 325(6101):279–281
Ross P, Mayer R, Weinhouse H, Amikam D, Huggirat Y, Benziman M, de Vroom E, Fidder A, de Paus P, Sliedregt LA et al (1990) The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives. J Biol Chem 265(31):18933–18943
Schwede F, Maronde E, Genieser H, Jastorff B (2000) Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther 87(2-3):199–226
Shanahan CA, Strobel SA (2012) The bacterial second messenger c-di-GMP: probing interactions with protein and RNA binding partners using cyclic dinucleotide analogs. Org Biomol Chem 10(46):9113–9129. doi:10.1039/c2ob26724a
Shanahan CA, Gaffney BL, Jones RA, Strobel SA (2011) Differential analogue binding by two classes of c-di-GMP riboswitches. J Am Chem Soc 133(39):15578–15592. doi:10.1021/ja204650q
Shanahan CA, Gaffney BL, Jones RA, Strobel SA (2013) Identification of c-di-GMP derivatives resistant to an EAL domain phosphodiesterase. Biochemistry 52(2):365–377. doi:10.1021/bi301510v
Sharma IM, Dhanaraman T, Mathew R, Chatterji D (2012) Synthesis and characterization of a fluorescent analogue of cyclic di-GMP. Biochemistry 51(27):5443–5453. doi:10.1021/bi3003617
Smith KD, Lipchock SV, Livinston AL, Shanahan CA, Strobel SA (2010) Structural and biochemical determinants of ligand binding by the c-di-GMP riboswitch. Biochemistry 49(34):7351–7359. doi:10.1021/bi100671e
Smith KD, Shanahan CA, Moore EL, Simon AC, Strobel SA (2011) Structural basis of differential ligand recognition by two classes of bis-(3′-5′)-cyclic dimeric guanosine monophosphate-binding riboswitches. Proc Natl Acad Sci U S A 108(19):7757–7762. doi:10.1073/pnas.1018857108
Sun L, Wu J, Du F, Chen X, Chen ZJ (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339(6121):786–791. doi:10.1126/science.1232458
Sundriyal A, Massa C, Samoray D, Zehender F, Sharpe T, Jenal U, Schirmer T (2014) Inherent regulation of EAL domain-catalyzed hydrolysis of second messenger cyclic di-GMP. J Biol Chem 289(10):6978–6990. doi:10.1074/jbc.M113.516195
Witte G, Hartung S, Büttner K, Hopfner KP (2008) Structural biochemistry of a bacterial checkpoint protein reveals diadenylate cyclase activity regulated by DNA recombination intermediates. Mol Cell 30(2):167–178. doi:10.1016/j.molcel.2008.02.020
Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ (2013) Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339(6121):826–830. doi:10.1126/science.1229963
Yan H, Aguilar AL (2007) Synthesis of 3′,5′-cyclic diguanylic acid (cdiGMP) using 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl as a protecting group for 2′-hydroxy functions of ribonucleosides. Nucleosides Nucleotides Nucleic Acids 26(2):189–204. doi:10.1080/15257770601112762
Yi G, Brendel VP, Shu C, Li P, Palanathan S, Cheng Kao C (2013) Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One 8(10), e77846. doi:10.1371/journal.pone.0077846
Zhang Z, Gaffney BL, Jones RA (2004) c-di-GMP displays a monovalent metal ion-dependent polymorphism. J Am Chem Soc 126(51):16700–16701. doi:10.1021/ja0449832
Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ (2013) Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51(2):226–235. doi:10.1016/j.molcel.2013.05.022
Zhao J, Veliath E, Kim S, Gaffney BL, Jones RA (2009) Thiophosphate analogs of c-di-GMP: impact on polymorphism. Nucleosides Nucleotides Nucleic Acids 28(5):352–378. doi:10.1080/15257770903044523
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Schwede, F., Genieser, HG., Rentsch, A. (2015). The Chemistry of the Noncanonical Cyclic Dinucleotide 2′3′-cGAMP and Its Analogs. In: Seifert, R. (eds) Non-canonical Cyclic Nucleotides. Handbook of Experimental Pharmacology, vol 238. Springer, Cham. https://doi.org/10.1007/164_2015_43
Download citation
DOI: https://doi.org/10.1007/164_2015_43
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52671-3
Online ISBN: 978-3-319-52673-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)